SAN FRANCISCO – Drugmakers targeting nonalcoholic steatohepatitis (NASH) unleashed a torrent of new data and plans at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in San Francisco over the weekend, including updates on late-stage studies and news of early progress on efforts to minimize reliance on invasive liver biopsies to identify patients with the disease.